Prelude Therapeutics IPO

9/24/2020

IPO

$158,175,000

Management says it will use the net proceeds from the IPO as follows:to advance the clinical development of PRT543, including to complete the dose escalation and expansion cohorts of our ongoing Phase 1 clinical trial in patients with solid tumors and hematological malignancies. We may be able to initiate Phase 2 clinical trial activities, but will require additional funding to complete the Phase 2 clinical trials;to advance the clinical development of PRT811, including to complete the dose escalation and expansion cohorts of our ongoing Phase 1 clinical trial in patients with advanced solid tumors. We may be able to initiate Phase 2 clinical trial activities, but will require additional funding to complete the Phase 2 clinical trials;to advance the clinical development of PRT1419, including to complete the dose escalation and expansion cohorts of our planned Phase 1 clinical trial in patients with R/R/ high risk MF or MDS and R/R NHL or MM;to fund further development of our preclinica

Publicly-held

Biopharmaceutical

200 Powder Mill Rd.
Wilmington, DE 19803
USA

Prelude (Nasdaq: PRLD) was founded in 2016 with the vision of bringing together the energy and collaborative culture of a start-up environment with experience in developing cancer medicines to create a next generation cancer drug discovery company.